Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.

ABSTRACT:

Importance

New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacterial resistance and safety concerns with standard care.

Objective

To evaluate the efficacy and adverse events of a 5-day oral lefamulin regimen in patients with CABP.

Design, setting, and participants

A phase 3, noninferiority randomized clinical trial conducted at 99 sites in 19 countries that included adults aged 18 years or older with a Pneumonia Outcomes Research Team (PORT) risk class of II, III, or IV; radiographically documented pneumonia; acute illness; 3 or more CABP symptoms; and 2 or more vital sign abnormalities. The first patient visit was on August 30, 2016, and patients were followed up for 30 days; the final follow-up visit was on

SUBMITTER: Alexander E 

PROVIDER: S-EPMC6865224 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature